NFL Biosciences: presentation to follow

Ignacio Faus, General Manager of NFL Biosciences, has been invited to present at the ‘HCWainwright 1ST Annual Mental Health Conference’, June 27-28, 2022.
On this occasion, NFL Biosciences will have the opportunity to present its activities and its development strategy to American professional investors. Ignacio Faus will detail in particular the implementation of the Phase II/III clinical study of the drug candidate NFL-101 for smoking cessation started in January 2022 in France. He will also discuss the co-development agreement for drug candidate NFL-301 to reduce alcohol consumption and the extension of intellectual property with the registration of the second patent of NFL-101 in the United States, China and in South Korea.

Laisser un commentaire